BridgeMD
Is dermal measles-mumps-rubella-vaccine administration better than regular injection?
EU CTIS ID: 2023-503845-79-01
What this study is testing
We will test in a randomized cross-over design in human volunteers, whether epicutaneous vaccination (EV) with the live attenuated Measles, Mumps, and Rubella (MMR) vaccine generates appropriate mucosal measles IgA response 3 months after receiving intervention
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 to 34 years. MMR-naive. Healthy. Safe contraception for female participants.
You likely can't join if
- Age < 18 or ≥ 35 years. MMR-vaccinated, or MMR wild type infected. Severe, chronic disease with potential implications for the immune response, or with anemia, or thrombocytopenia. Allergy towards any vaccine component (egg, neomycin). Fructose intolerance. Blood, or plasma, or human immune serum globulin transfusion within 3 months. Pregnancy or breastfeeding.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.